Glucose-dependent insulinotropic polypeptide Glucose-dependent insulinotropic polypeptide (GIP), historically known as gastric inhibitory peptide, is a crucial hormone within the incretin system. Primarily secreted by K cells in the upper small intestine, GIP plays a significant role in regulating glucose homeostasis. Its release is triggered by the presence of nutrients, particularly glucose and fats, following a meal. GIP's main actions involve potentiating glucose-induced insulin secretion from pancreatic beta cells and reducing gastric emptying, thereby influencing nutrient absorption and overall metabolic control.
GIP is a central component of the incretin effect, a phenomenon where oral glucose administration stimulates a greater insulin response compared to intravenous glucose administration at equivalent blood glucose levels. This enhanced insulin secretion is largely mediated by incretin hormones, with GIP and glucagon-like peptide-1 (GLP-1) being the primary players.
When food, especially carbohydrates and fats, enters the duodenum and jejunum, enteroendocrine K cells release GIP into the bloodstreamGastric inhibitory polypeptide (GIP) is a hormone secreted by cells in the upper small intestine that has two main actions:it potentiates glucose-induced insulin secretionand reduces gastric emptying.From: Physiology and Anatomy for Nurses and Healthcare Practitioners [2019], The Glycemic Index [2019], .... This peptide then travels to the pancreas, where it binds to the GIP receptor (GIPR) on beta cells. This binding significantly amplifies the insulinotropic effect of elevated blood glucose, leading to increased insulin release.Gastric inhibitory polypeptide and glucagon-like peptide-1 ... This mechanism is vital for efficiently clearing glucose from the bloodstream after a meal.
However, the role of GIP is not solely confined to insulin secretion. It also influences gastric function by slowing down the rate at which the stomach empties its contents into the small intestine. This delay in gastric emptying contributes to a more gradual absorption of nutrients and can influence satiety.
The intricate relationship between GIP and glucose metabolism has made it a subject of intense research, particularly in the context of diabetes and obesityDipeptidyl‐peptidase IV hydrolyses gastric inhibitory .... In individuals with type 2 diabetes, the sensitivity of pancreatic beta cells to GIP's insulinotropic effects is often impaired, a condition known as GIP resistance. Despite this, GIP levels can be elevated in obesity and type 2 diabetes.
Recent therapeutic strategies have focused on modulating the GIP system. For instance, GIP receptor agonists are being explored for their potential to enhance glucose control. Furthermore, combination therapies involving GIP receptor agonists alongside GLP-1 receptor agonists have shown promising results in promoting significant weight loss and improving glycemic control, suggesting a synergistic effect between these two incretin pathways.Conclusion and ImplicationsmGIPAnt‐1 successfully inhibited acute GIP‐induced effectsin vitro and in vivo and sub‐chronically induces resistance to HFD‐ ... Molecules and peptides that interact with GIP, such as GIP(3-30)NH2, have been studied for their ability to block GIP receptor activity, offering insights into potential therapeutic interventions.
Like other peptide hormones, GIP is subject to enzymatic degradation. Dipeptidyl peptidase-4 (DPP-4) is a key enzyme responsible for breaking down GIP in the circulation.Glucose‐dependent insulinotropic polypeptide receptor ... DPP-4 inhibitors, a class of drugs commonly used to manage type 2 diabetes, work by preventing the degradation of incretin hormones, including GIP and GLP-1.A gastrointestinalpeptidehormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of ... By inhibiting DPP-4, these drugs increase the circulating levels and prolong the activity of endogenous incretins, thereby improving glycemic control through enhanced insulin secretion and reduced glucagon release. The precise contribution of GIP protection versus GLP-1 protection to the overall clinical benefits of DPP-4 inhibitors is an ongoing area of investigation.Alternative form of glucose‐dependent insulinotropic ...
While its role in glucose metabolism is well-established, research is uncovering additional functions of GIP.Gastric inhibitory polypeptide and glucagon-like peptide-1 ... Studies suggest that GIP may also influence lipid metabolism and even have effects on adipose tissue.Abbreviated name: GIP ; Synonyms:gastric inhibitory peptide| glucose-dependent insulinotropic polypeptide ; Compound class: Endogenous peptide in human, mouse ... The development of GIP-based molecules and therapeutic agents highlights the expanding understanding of this hormone's multifaceted impact on metabolic health. The exploration of alternative forms, such as GIP1-30, which is expressed in pancreatic alpha cells and some gut endocrine cells, further points to the complexity and therapeutic potential of the GIP system作者：MA Nauck·2004·被引用次数：307—The two hormones responsible for the incretin effect,glucose-dependent insulinotropic hormone (GIP) and glucagon-like peptide-1 (GLP-1), are secreted after ....
In summary, glucose-dependent insulinotropic polypeptide (GIP) is a vital gut hormone that orchestrates crucial aspects of post-meal glucose regulation. Its ability to stimulate insulin secretion and influence gastric emptying positions it as a key player in maintaining metabolic balance. Ongoing research into the GIP system, including its interaction with GLP-1 and its degradation by DPP-4, continues to unlock new therapeutic avenues for metabolic diseases like diabetes and obesity.
Join the newsletter to receive news, updates, new products and freebies in your inbox.